CRISPR Therapeutics Reports Q1 Loss, Misses Revenue Estimates

CRISPR Therapeutics reported a wider-than-expected loss of $1.58 per share for the first quarter, missing analyst estimates, though revenue grew 72% year-over-year to $0.86–$0.87 million. Despite the loss, the company highlighted progress in its clinical pipeline and expressed optimism about future updates, particularly for its in vivo gene-editing therapies and the gradual rollout of Casgevy. Analysts remain generally positive, with several maintaining Buy or Outperform ratings, but some lowered their price targets following the earnings miss, citing the need for more reasonable expectations. The average one-year price target among analysts is around $81, suggesting significant upside from current levels, though some valuation models, like GuruFocus, estimate a potential downside. Institutional investors have continued to increase their holdings in CRISPR Therapeutics, reflecting ongoing interest in the company's prospects. However, the stock has underperformed the broader market year-to-date, and near-term movements are expected to depend on future earnings outlook and management's commentary.